Overcoming biotherapeutic protein expression challenges with advanced vector technology for a range of multi-gene and difficult to express proteins

The development of biotherapeutic products is complex and the growing prevalence of next-generation and difficult-to-express formats places increasing demands on CHO expression systems to deliver high yield, scalable, and quality-consistent bioproduction. Maximizing the potential of an expression system requires precise coordination between various elements of upstream production, starting with the crucial first step of DNA vector design. In this presentation, we detail how Lonza developed the advanced GSquad Pro® expression vector technology that can power high titers, excellent product quality and long-term expression stability for a range of product types. We’ll cover how implementing a proven expression system early in development can help pave the way for successful biotherapeutic drug development, whatever the molecule type.